Search
Close
  • Products & Technology
    • T2Dx Instrument
    • T2Bacteria Panel
    • T2Candida Panel
    • T2SARS-CoV-2 Panel
    • T2MR Technology
    • Product Pipeline
      • BARDA
      • T2Resistance Panel
      • T2Lyme Panel
      • T2Cauris Panel
      • T2Biothreat Panel
  • Healthcare Challenges
    • Sepsis
    • COVID-19
    • Lyme Disease
  • Resources
    • Publications
    • Case Studies
    • Webinars & Videos
  • About T2
    • Our Company
    • Our Mission
    • News
    • Leadership
    • Careers
    • Events
    • Research Partnerships
    • International Distributors
    • FAQ
    • Media Resources
Menu
  • Products & Technology
    • T2Dx Instrument
    • T2Bacteria Panel
    • T2Candida Panel
    • T2SARS-CoV-2 Panel
    • T2MR Technology
    • Product Pipeline
      • BARDA
      • T2Resistance Panel
      • T2Lyme Panel
      • T2Cauris Panel
      • T2Biothreat Panel
  • Healthcare Challenges
    • Sepsis
    • COVID-19
    • Lyme Disease
  • Resources
    • Publications
    • Case Studies
    • Webinars & Videos
  • About T2
    • Our Company
    • Our Mission
    • News
    • Leadership
    • Careers
    • Events
    • Research Partnerships
    • International Distributors
    • FAQ
    • Media Resources
  • Products & Technology
    • T2Bacteria Panel
    • T2Candida Panel
    • T2Resistance Panel
    • T2Dx Instrument
    • T2MR Technology
    • Product Pipeline
      • T2Biothreat Panel
      • T2Lyme Panel
      • T2Cauris Panel RUO
  • Healthcare Challenges
    • Sepsis
    • COVID-19
    • Lyme Disease
  • Resources
    • Publications
    • Webinars & Videos
    • Case Studies
  • About T2
    • Our Company
    • Our Mission
    • News
    • Leadership
    • Careers
    • Events
    • Research Partnerships International
    • Distributors
    • FAQ
    • Media Resources
Menu
  • Products & Technology
    • T2Bacteria Panel
    • T2Candida Panel
    • T2Resistance Panel
    • T2Dx Instrument
    • T2MR Technology
    • Product Pipeline
      • T2Biothreat Panel
      • T2Lyme Panel
      • T2Cauris Panel RUO
  • Healthcare Challenges
    • Sepsis
    • COVID-19
    • Lyme Disease
  • Resources
    • Publications
    • Webinars & Videos
    • Case Studies
  • About T2
    • Our Company
    • Our Mission
    • News
    • Leadership
    • Careers
    • Events
    • Research Partnerships International
    • Distributors
    • FAQ
    • Media Resources
  • Investors
  • Technical Support
  • Contact Us
Menu
  • Investors
  • Technical Support
  • Contact Us
  • Investors
  • Contact Us
Menu
  • Investors
  • Contact Us
Schedule a Meeting
Search
Close
  • Products & Technology
    • T2Dx Instrument
    • T2Bacteria Panel
    • T2Candida Panel
    • T2SARS-CoV-2 Panel
    • T2MR Technology
    • Product Pipeline
      • BARDA
      • T2Resistance Panel
      • T2Lyme Panel
      • T2Cauris Panel
      • T2Biothreat Panel
  • Healthcare Challenges
    • Sepsis
    • COVID-19
    • Lyme Disease
  • Resources
    • Publications
    • Case Studies
    • Webinars & Videos
  • About T2
    • Our Company
    • Our Mission
    • News
    • Leadership
    • Careers
    • Events
    • Research Partnerships
    • International Distributors
    • FAQ
    • Media Resources
Menu
  • Products & Technology
    • T2Dx Instrument
    • T2Bacteria Panel
    • T2Candida Panel
    • T2SARS-CoV-2 Panel
    • T2MR Technology
    • Product Pipeline
      • BARDA
      • T2Resistance Panel
      • T2Lyme Panel
      • T2Cauris Panel
      • T2Biothreat Panel
  • Healthcare Challenges
    • Sepsis
    • COVID-19
    • Lyme Disease
  • Resources
    • Publications
    • Case Studies
    • Webinars & Videos
  • About T2
    • Our Company
    • Our Mission
    • News
    • Leadership
    • Careers
    • Events
    • Research Partnerships
    • International Distributors
    • FAQ
    • Media Resources
  • Products & Technology
    • T2Bacteria Panel
    • T2Candida Panel
    • T2Resistance Panel
    • T2Dx Instrument
    • T2MR Technology
    • Product Pipeline
      • T2Biothreat Panel
      • T2Lyme Panel
      • T2Cauris Panel RUO
  • Healthcare Challenges
    • Sepsis
    • COVID-19
    • Lyme Disease
  • Resources
    • Publications
    • Webinars & Videos
    • Case Studies
  • About T2
    • Our Company
    • Our Mission
    • News
    • Leadership
    • Careers
    • Events
    • Research Partnerships International
    • Distributors
    • FAQ
    • Media Resources
Menu
  • Products & Technology
    • T2Bacteria Panel
    • T2Candida Panel
    • T2Resistance Panel
    • T2Dx Instrument
    • T2MR Technology
    • Product Pipeline
      • T2Biothreat Panel
      • T2Lyme Panel
      • T2Cauris Panel RUO
  • Healthcare Challenges
    • Sepsis
    • COVID-19
    • Lyme Disease
  • Resources
    • Publications
    • Webinars & Videos
    • Case Studies
  • About T2
    • Our Company
    • Our Mission
    • News
    • Leadership
    • Careers
    • Events
    • Research Partnerships International
    • Distributors
    • FAQ
    • Media Resources

Performance of the T2Resistance Panel in Detecting Antibiotic Resistance Bacteria Directly in Whole Blood…

T2 BIOSYSTEMS OVERVIEW

T2 Biosystems, an emerging leader in the field of in vitro diagnostics, is dedicated to saving lives and reducing the cost of healthcare by empowering clinicians to effectively treat patients faster than ever before. T2 Biosystems is focused on addressing critical unmet needs in healthcare starting with sepsis, one of the deadliest and most expensive conditions in hospitals today.

The T2Dx Instrument, the T2Bacteria and T2Candida Panels have received marketing authorization from the U.S. Food and Drug Administration. All other T2 Biosystems products are considered investigational and for research use only.

T2 Biosystems®, T2MR®, T2Bacteria®, T2Candida®, and T2Dx® are registered trademarks of T2 Biosystems, Inc. “T2Biosystems” and the T2 Biosystems, Inc. logo design are registered trademarks or trademarks of T2Biosystems, Inc. All software and documentation is subject to T2 Biosystems, Inc. copyrights. All rights reserved. T2Direct Diagnostics™, T2HemoStat™, T2Plex™, T2Cauris™, T2Resistance™ and T2SARS-CoV-2™ are trademarks of T2 Biosystems, Inc.

© 2022 T2 Biosystems, Inc.

JOIN IN ON TWITTER

T2 Biosystems
@T2Bio

A recent systematic review and meta-analysis published in @TheLancet found that roughly 60% of bacterial co-infections or secondary infections in #COVID19 patients were resistant to antimicrobials.

  • February 3, 2023
T2 Biosystems
@T2Bio

Sepsis has been included in the federal budget, thanks to the advocacy of organizations like @EndSepsis. The budget directs funding for comprehensively studying the burden of sepsis in the US healthcare system and a review of sepsis quality measures.

  • January 30, 2023

SITEMAP

  • T2MR Technology
  • T2Bacteria Panel
  • T2Candida Panel
  • Product Pipeline
  • T2Dx Instrument
  • Terms of Use & Privacy Policy
  • Standard Terms & Conditions
Menu
  • T2MR Technology
  • T2Bacteria Panel
  • T2Candida Panel
  • Product Pipeline
  • T2Dx Instrument
  • Terms of Use & Privacy Policy
  • Standard Terms & Conditions

FOLLOW US ON SOCIAL

Linkedin-in Twitter
  • About T2
  • Investors
  • Technical Support
  • Careers
  • Contact Us
  • Conflict Minerals Report
  • T2 Compliance Program
  • Declaration of Compliance
Menu
  • About T2
  • Investors
  • Technical Support
  • Careers
  • Contact Us
  • Conflict Minerals Report
  • T2 Compliance Program
  • Declaration of Compliance

Please tell us where you are visiting from: United States | Outside the United States